Anil K. Rustgi
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Role of IMP1 in the pathogenesis of Inflammatory Bowel Disease
Open Date: 2014-07-01
Close Date: 2017-06-30
Grant: Close
CAPS multicenter trial: Imaging and markers for pancreatic cancer screening
Open Date: 2013-07-01
Close Date: 2017-06-30
Grant: Close
The Role of the Microenvironment in Barrett's Esophagus
Open Date: 2011-09-26
Close Date: 2022-04-30
Grant: Close
Impact of Radiation Quality on Cancer Processes in 2D and 3D Esophageal Cell Models
Open Date: 2009-11-15
Close Date: 2013-09-01
Grant: Close
The Intestinal Stem Cell Niche
Open Date: 2009-09-30
Close Date: 2015-08-31
Articles (4)
S1. Frequency of Pan-IN lesion types in KC versus KCC mice. S2. Re-expression of Ch25h in PDAC cell lines. S3. Presence of exogenous lipids diminishes effect of Ch25h re-expression in PDAC. S4. Re-expression of Ch25h does not affect Ras localization. S5. CH25H decreases autophagic flux in PDAC cells. S6. Ch25h slows PDAC tumor growth.
Year:
2025
Cholesterol dependence is an essential characteristic of pancreatic ductal adenocarcinoma (PDAC). Cholesterol 25-hydroxylase (CH25H) catalyzes monooxygenation of cholesterol into 25-hydroxycholesterol, which is implicated in inhibiting cholesterol biosynthesis and in cholesterol depletion. Here, we show that, within PDAC cells, accumulation of cholesterol was facilitated by the loss of CH25H. Methylation of the CH25H gene and decreased levels of CH25H expression occurred in human pancreatic cancers and was associated with poor prognosis. Knockout of Ch25h in mice accelerated progression of Kras -driven pancreatic intraepithelial neoplasia. Conversely, restoration of CH25H expression in human and mouse PDAC cells decreased their viability under conditions of cholesterol deficit, and decelerated tumor growth in immune competent hosts. Mechanistically, the loss of CH25H promoted autophagy resulting in downregulation of MHC-I and decreased CD8 + T-cell tumor infiltration. Re-expression of CH25H in PDAC cells combined with immune checkpoint inhibitors notably inhibited tumor growth. We discuss additional benefits that PDAC cells might gain from inactivation of CH25H and the potential translational importance of these findings for therapeutic approaches to PDAC. Implications: Loss of CH25H by pancreatic cancer cells may stimulate tumor progression and interfere with immunotherapies.
Year:
2025
Cancer-associated fibroblasts (CAFs) can promote tumor growth, metastasis and therapeutic resistance in esophageal squamous cell carcinoma (ESCC), but the mechanisms of action remain elusive. Our objective was to identify secreted factor(s) that mediate the communication between CAFs and ESCC tumor cells with the aim of identifying potential druggable targets. Through unbiased cytokine arrays, we have identified CC motif chemokine ligand 5 (CCL5) as a secreted factor that is increased upon co-culture of ESCC cells and CAFs, which we replicated in esophageal adenocarcinoma (EAC) with CAFs. Loss of tumor-cell derived CCL5 reduces ESCC cell proliferation in vitro and in vivo and we propose this is mediated, in part, by a reduction in ERK1/2 signaling. Loss of tumor-derived CCL5 reduces the percentage of CAFs recruited to xenograft tumors in vivo. CCL5 is a ligand for the CC motif receptor 5 (CCR5), for which a clinically approved inhibitor exists, namely Maraviroc. Maraviroc treatment reduced tumor volume, CAF recruitment and ERK1/2 signaling in vivo, thus, mimicking the effects observed with genetic loss of CCL5. High CCL5 or CCR5 expression is associated with worse prognosis in low grade esophageal carcinomas. Implications: These data highlight the role of CCL5 in tumorigenesis and the therapeutic potential of targeting the CCL5-CCR5 axis in ESCC.
Year:
2024
TP53 mutations are frequent in esophageal squamous cell carcinoma (ESCC) and other SCCs and are associated with a proclivity for metastasis. Here, we report that colony-stimulating factor-1 (CSF-1) expression is upregulated significantly in a p53-R172H–dependent manner in metastatic lung lesions of ESCC. The p53-R172H–dependent CSF-1 signaling, through its cognate receptor CSF-1R, increases tumor cell invasion and lung metastasis, which in turn is mediated in part through Stat3 phosphorylation and epithelial-to-mesenchymal transition (EMT). In Trp53R172H tumor cells, p53 occupies the Csf-1 promoter. The Csf-1 locus is enriched with histone 3 lysine 27 acetylation (H3K27ac), which is likely permissive for fostering an interaction between bromodomain-containing domain 4 (BRD4) and p53-R172H to regulate Csf-1 transcription. Inhibition of BRD4 not only reduces tumor invasion and lung metastasis but also reduces circulating CSF-1 levels. Overall, our results establish a novel p53-R172H–dependent BRD4–CSF-1 axis that promotes ESCC lung metastasis and suggest avenues for therapeutic strategies for this difficult-to-treat disease. Significance: The invasion–metastasis cascade is a recalcitrant barrier to effective cancer therapy. We establish that the p53-R172H–dependent BRD4-CSF-1 axis is a mediator of prometastatic properties, correlates with patient survival and tumor stages, and its inhibition significantly reduces tumor cell invasion and lung metastasis. This axis can be exploited for therapeutic advantage. This article is featured in Selected Articles from This Issue, p. 2489
Year:
2023
Collaborators (12)
Jianhua Hu
Columbia University Irving Medical Center
Pengfei Yu
University of Pennsylvania
Ben Stanger
University of Pennsylvania
Jason Pitarresi
Assistant professor
University of Massachusetts Chan Medical School
J. Alan Diehl
University of Pennsylvania
Hiroshi Nakagawa
Professor
Columbia University
Serge Y. Fuchs
University of Pennsylvania
Tatiana A Karakasheva
Research Associate, Gastrointestinal Modeling Program (GEM)
Children's Hospital of Philadelphia
Igor Astsaturov
Professor
Fox Chase Cancer Center
Hallgeir Rui
Professor
Thomas Jefferson University
Enrico Radaelli
Associate Professor
University of Pennsylvania
Christina Cho
Assistant Professor
The University of Iowa
Make your next move.
Prepare your application
Review drafts before you send them.